tokens: At low baseline lipoprotein(a ) levels , alirocumab tended to reduce incident type 2 diabetes , while at high baseline lipoprotein(a ) alirocumab tended to increase incident type 2 diabetes compared with placebo ( treatment - baseline lipoprotein(a ) interaction P = 0.006 ) .